Traws Pharma Stock Jumps As Biotech Targets Hantavirus After Cruise Ship Deaths

Traws Pharma Inc. on Friday announced plans to push ahead with possible clinical candidates targeting hantavirus infections, shifting the antiviral developer’s focus after a lethal outbreak on a cruise ship. The company hasn’t disclosed a frontrunner. Chief Scientific Officer C. David Pauza said Traws “plans to rapidly advance clinical candidates.” Chief Medical Officer Robert R. Redfield described the move as an emergency push for “life-saving treatments.”

8 May 2026

Novavax, Inc. Stock Jumps: Why Pfizer’s Matrix-M Deal Drove a Surprise Q1 Revenue Beat

Novavax Inc. shares climbed as the vaccine maker’s first-quarter revenue topped Wall Street forecasts, lifted not by COVID-19 shot demand but by licensing and supply payments linked to its vaccine technology. Revenue came in at $139.5 million, Reuters said, beating analysts’ $78.3 million estimate from LSEG data.

7 May 2026

Earnings·NASDAQ:NVAX·Pharmaceuticals

Bayer’s $2.45 Billion Perfuse Deal Puts Eye-Drug Pipeline Back in Focus

Bayer on Wednesday announced plans to acquire Perfuse Therapeutics for as much as $2.45 billion, targeting a mid-stage drug candidate for eye disease as it looks to reinforce its ophthalmology unit. The German company is putting down $300 million upfront; future payouts will hinge on how the drug progresses through development, regulatory hurdles, and eventual sales.

6 May 2026

Biotechnology·Pharmaceuticals·XETRA:BAYN

Novavax Stock Jumps as Pfizer Vaccine Deal Drives Big Q1 Revenue Beat

Novavax shares jumped Wednesday. The vaccine maker’s first-quarter revenue came in far ahead of Wall Street forecasts, buoyed by a $30 million payment from Pfizer and partner revenue, not from COVID-19 shot sales.

6 May 2026

Earnings Reports·NASDAQ:NVAX·Pharmaceuticals

Novo Nordisk Stock Jumps After Wegovy Pill Sales Surprise in Lilly Obesity Fight

Novo Nordisk bumped up its 2026 forecast on Wednesday, buoyed by stronger-than-expected initial sales for its Wegovy weight-loss pill—a fresh win in its rivalry with Eli Lilly. In Copenhagen, the stock jumped up to 9.2% after Novo told investors it now expects this year’s drops in sales and profit to be less steep than it previously warned.

6 May 2026

NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Pfizer Earnings Beat Wall Street, But The Patent Cliff Is Still The Story

Pfizer turned in a first-quarter profit that beat forecasts on Tuesday, thanks in large part to solid demand for established drugs like the blood thinner Eliquis and cancer therapy Padcev, cushioning the impact of another steep fall in sales of its COVID offerings. Adjusted earnings landed at 75 cents per share, with revenue reaching $14.45 billion—both topping Wall Street’s consensus for 72 cents per share and $13.79 billion in revenue, according to Reuters.

5 May 2026

Earnings Reports·NYSE:PFE·Pharmaceuticals·Stock Market

Mirum Stock Jumps After Volixibat Trial Win Puts First PSC Itch Drug Within Reach

Shares of Mirum Pharmaceuticals surged Monday, after the company announced its experimental therapy volixibat hit the primary endpoint in a Phase 2b study targeting primary sclerosing cholangitis, or PSC—a rare liver condition marked by scarring of the bile ducts and potential liver failure. The study zeroed in on cholestatic pruritus, the intense itching caused by impaired bile flow and notorious as one of PSC’s toughest symptoms.

4 May 2026

Biotechnology·NASDAQ:MIRM·Pharmaceuticals

Recursion Pharmaceuticals Stock: Founder Chris Gibson to Leave Board as RXRX Nears Q1 Earnings

Recursion Pharmaceuticals announced that founder and board chair Chris Gibson won’t seek re-election at this year’s annual meeting, marking another step back from direct oversight after he exited the chief executive role a few months ago. CEO Najat Khan insisted the company stays committed to “continuity and long-term value creation.” Gibson described his time building Recursion as “one of the most rewarding journeys.”

1 May 2026

Earnings Reports·NASDAQ:RXRX·Pharmaceuticals

Cue Biopharma Stock Nearly Doubles After Allergy Drug Deal, New CEO and $30 Million Raise

Cue Biopharma surged Friday morning, the stock boosted by news of a fresh allergy drug license. The Boston biotech also unveiled a $30 million private placement and named Shao-Lee Lin as its new chief executive.

1 May 2026

NASDAQ:CUE·Pharmaceuticals

Moderna Revenue Beat: Overseas Covid Shot Sales Jump, but $900 Million Charge Clouds the Turnaround

Moderna Inc. topped first-quarter revenue forecasts Friday, with international Covid-19 vaccine sales outpacing what the U.S. market delivered—setting the biotech up for a stronger 2026 kickoff than many investors had penciled in. Revenue hit $389 million, a jump from $108 million the previous year, and of that, $311 million was generated outside the U.S.)

1 May 2026

NASDAQ:MRNA·Pharmaceuticals

Eli Lilly Raises 2026 Forecast as Mounjaro, Zepbound Sales Keep Weight-Loss Boom Alive

Eli Lilly hiked its full-year outlook for both sales and profit Thursday, following a jump in quarterly revenue driven by strong uptake of its diabetes drug Mounjaro and obesity therapy Zepbound. First-quarter revenue climbed 56% to $19.8 billion, according to the Indianapolis-based company, with adjusted earnings coming in at $8.55 per share.

30 April 2026

Financial Forecasts·NYSE:LLY·Pharmaceuticals

Teva Stock Jumps As Branded Drugs Start Carrying The Old Generics Giant

Teva Pharmaceutical Industries shares rallied in New York on Wednesday, with the Israeli drugmaker topping first-quarter profit forecasts. Results benefited from a quicker pivot to branded drugs and reduced exposure to lower-margin generics. For investors, it’s a more direct look at Chief Executive Richard Francis’s turnaround efforts—showing more than another quarter of trimming expenses.

29 April 2026

NYSE:TEVA·Pharmaceuticals·Stock Market

Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge

Biogen Inc. trimmed its profit forecast for the year on Wednesday, even after first-quarter earnings came in ahead of expectations thanks to solid sales from Alzheimer’s treatment Leqembi and fresh rare-disease drugs.

29 April 2026

Earnings·NASDAQ:BIIB·Pharmaceuticals·Stock Market

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Pharmaceuticals topped analyst forecasts for first-quarter revenue and earnings Wednesday, powered by gains from Dupixent and Libtayo that balanced out softer Eylea sales. Still, shares slipped 1.1% before the bell.

29 April 2026

Earnings Reports·NASDAQ:REGN·Pharmaceuticals·Stock Market

Sagimet Stock Surges as $175 Million Raise Sharpens Acne Drug Push

Sagimet Biosciences Inc. shares surged Monday, after the company set terms for a $175 million stock sale and signaled plans to funnel proceeds into a pivotal U.S. acne study for denifanstat—dermatology now takes priority in its pipeline. Sagimet is offering 29,166,700 Series A common shares at $6 each, targeting a closing date near April 28.

27 April 2026

NASDAQ:SGMT·Pharmaceuticals·Stock Market

Veradermics Stock Jumps After VDPHL01 Hair-Loss Pill Hits Trial Goals

Veradermics, Incorporated shares surged Monday, after the company reported its experimental oral hair-loss treatment, VDPHL01, hit all main and key secondary endpoints in a Phase 2/3 study of men with mild-to-moderate pattern hair loss. The Phase 2/3 trial—a mid- to late-stage human study—is designed to assess safety and efficacy ahead of a potential approval filing.

27 April 2026

NYSE:MANE·Pharmaceuticals·Stock Market

Eli Lilly’s New Weight-Loss Pill Has an Early Problem: Novo’s Head Start

Prescriptions for Eli Lilly and Company’s new oral weight-loss drug Foundayo reached 3,707 in the U.S. during its second week, according to IQVIA data cited by analysts. That’s behind the early numbers seen for Novo Nordisk’s competing Wegovy pill and has weighed on Lilly shares. In its launch week, Foundayo saw 1,390 prescriptions.

24 April 2026

Health News·NYSE:LLY·NYSE:NVO·Pharmaceuticals

Novo Nordisk Stock Gets Wegovy Pill Boost as Eli Lilly’s Foundayo Starts Slow

Novo Nordisk A/S’s Wegovy pill stayed ahead in the early going, with 18,410 U.S. prescriptions at the same stage of launch where Eli Lilly’s Foundayo managed 3,707 in its second week, according to analysts referencing IQVIA data. RBC Capital Markets analyst Trung Huynh flagged that it’s early days and comparisons can be tricky, but noted that Foundayo’s latest numbers are likely to be viewed as a disappointment.

24 April 2026

NYSE:LLY·NYSE:NVO·Pharmaceuticals

Regeneron Stock Is Back In Focus: Why Wall Street Sees More Upside After Trump Deal

Regeneron Pharmaceuticals caught Wall Street’s attention again—investors now have more to chew on after a U.S. drug-pricing agreement, a unique FDA approval, and new backing from analysts, all ahead of next week’s earnings report.

24 April 2026

NASDAQ:REGN·Pharmaceuticals·Stock Market

Hims Adds Lilly’s Zepbound and Foundayo as GLP-1 Price Fight Moves Online

Hims & Hers Health announced Thursday that its providers are now able to send prescriptions for Eli Lilly’s Zepbound vials, the Zepbound KwikPen, and the Foundayo pill directly to LillyDirect. With this move, the telehealth company is expanding its reach into branded obesity treatments. The company said that, combined with its previous Novo Nordisk partnership, it now offers what it describes as the full lineup of FDA-approved GLP-1 drugs on its platform.

23 April 2026

NYSE:HIMS·NYSE:LLY·NYSE:NVO·Pharmaceuticals